Q2 25 EPS
$0.00
BEAT +100.00%
Est. $-1.17
Q2 25 Revenue
$160.0M
BEAT +386.96%
Est. $32.9M
vs S&P Since Q2 25
+185.3%
BEATING MARKET
RCUS +204.7% vs S&P +19.4%
Market Reaction
Did RCUS Beat Earnings? Q2 2025 Results
Arcus Biosciences delivered a dramatic beat in Q2 2025, with revenue surging 310.3% year-over-year to $160.00 million against a consensus estimate of just $32.86 million, a 386.96% upside surprise, while EPS landed at $0.00, beating the $-1.17 consen… Read more Arcus Biosciences delivered a dramatic beat in Q2 2025, with revenue surging 310.3% year-over-year to $160.00 million against a consensus estimate of just $32.86 million, a 386.96% upside surprise, while EPS landed at $0.00, beating the $-1.17 consensus by 100.00% and representing a sharp reversal from the $-1.02 reported in the prior-year quarter. The headline numbers were overwhelmingly shaped by a $143.00 million cumulative catch-up revenue recognition tied to Gilead returning its license to etrumadenant in June 2025, an event that effectively zeroed out net income versus a $93.00 million loss a year ago. Stripping away that one-time item, Arcus remains a clinical-stage company with a sharpened focus on casdatifan, domvanalimab, and quemliclustat. R&D spending rose to $139.00 million, though management expects costs to decline starting Q4 as domvanalimab Phase 3 expenses ease. With $927.00 million in cash on hand and full-year 2025 revenue guidance set at $225.00 to $235.00 million, Arcus believes it is funded through initial pivotal readouts across its core pipeline.
Key Takeaways
- • $143 million cumulative catch-up revenue from pausing etrumadenant development and Gilead's return of its license
- • Increased CMC costs driving higher R&D expenses
- • February 2025 underwritten offering and $50 million term loan draw in June 2025 supporting cash position
RCUS YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
RCUS Revenue by Segment
With YoY comparisons, source: SEC Filings
“We have now presented data from over 125 patients treated with casdatifan monotherapy or casdatifan plus cabozantinib, which we believe demonstrate the potential for casdatifan to be the best-in-class HIF-2a inhibitor for clear cell RCC.”
— Terry Rosen, Q2 2025 Earnings Press Release
RCUS Earnings Trends
RCUS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
RCUS EPS Trend
Earnings per share: estimate vs actual
RCUS Revenue Trend
Quarterly revenue: estimate vs actual
RCUS Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.83 | $-1.02 | -23.26% | $17.0M | -42.34% |
| Q4 25 BEAT FY | $-1.01 | $-0.89 | +11.59% | $33.0M | +25.00% |
| FY Full Year | $-3.50 | $-3.29 | +6.00% | $247.0M | +3.96% |
| Q3 25 BEAT | $-1.29 | $-1.27 | +1.57% | $26.0M | +28.40% |
| Q2 25 BEAT | $-1.17 | $0.00 | +100.00% | $160.0M | +386.96% |
| Q1 25 MISS | $-1.01 | $-1.14 | -12.61% | $28.0M | -27.47% |